Novartis India Limited

BSE: 500672 NSE: NOVARTIND
Novartis India Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24200MH1947PLC006104 Incorporated 13 December 1947 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: NOVARTIND · BSE: 500672 Public Limited Company pharma
Data last updated
Market Cap
₹4,476 Cr
NOVARTIND · NSE
Share Price
₹1,692.40
-6.64% today
Revenue
₹377 Cr
FY 2025-26 · -3.4% YoY
EBITDA
₹94.10 Cr
Margin 25.0%
Net Profit
₹93.20 Cr
FY 2025-26 · -7.5% YoY
P/E (TTM)
46.0x
P/B 5.5x
ROE
11.6%
ROCE 15.9%
Debt / Equity
0.01
Interest cover 1.4x

About Novartis India Limited

Data last updated:

Novartis India Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Novartis Ag. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 13 December 1947 and has been in existence for over 79 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24200MH1947PLC006104. Its GSTIN is 27AAACH2914F1ZY (Maharashtra). The company holds 24 GST registrations, of which 23 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500672 and NSE: NOVARTIND.

The company has an authorised share capital of ₹32 Cr and a paid-up capital of ₹12.35 Cr. It was formerly known as Ciba (India) Private Limited and Ciba (India) Limited. It is led by directors including Shilpa Shashank Joshi (Whole-Time Director) and Falin Ishwarlal Majmudar (Whole-Time Director).

Its last annual general meeting (AGM) was held on 31 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹376.96 Cr, a decline of 3.4% compared to the previous year. For the same year it recorded a net profit of ₹93.2 Cr (net margin 24.7%) and EBITDA of ₹94.1 Cr (EBITDA margin 25%). The net worth stands at ₹817.83 Cr (up 4.2% YoY). Total assets are valued at ₹834.94 Cr (up 3.4% YoY).

The company has about 59 employees on its provident fund (EPFO) records.

As per MCA filings, the company has satisfied charges of ₹257.48 Cr on record. Court records list 344 cases involving the company, including 173 filed by the company and 175 filed against it; 57 cases are pending. The company has 12 deals on record (8 market trades, 4 secondary share transfers); the latest was in September 2026. The company has 15 MSME Form 1 returns on record between 2019 and 2024, listing 1,341 overdue payments to 43 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website novartis.in.

Company details

CIN L24200MH1947PLC006104
Registration Number 006104
Incorporation Date 13 December 1947
ROC Mumbai
Listing Status Listed - Listed on NSE (NOVARTIND); Listed on BSE (500672)
Company Status Active
Date of Last AGM 31 July 2025
Date of Balance Sheet 31 March 2026
Parent Company Novartis Ag
Compliance Status Active Compliant

Name history

Novartis India has undergone 2 name changes throughout its history. The company was previously known as Ciba (India) Private Limited, and Ciba (India) Limited. The current legal name is Novartis India Limited.

Company NameStatus
Novartis India LimitedCurrent
Ciba (India) Private LimitedPrevious
Ciba (India) LimitedPrevious
Key People
Shilpa Shashank Joshi Whole-Time Director Falin Ishwarlal Majmudar Whole-Time Director Sanker Parameswaran Director

Contact details

Novartis India Limited's registered office is in Mumbai, Maharashtra. Its website is novartis.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    novartis.in
  • Social Media
  • Registered Address
    Inspire BKC 7th Floor Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra, India – 400051
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Novartis India Limited, buy the company report.

Comprehensive company report
Novartis India Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Novartis India is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Novartis India Limited, buy the company report.

Financials of Novartis India Limited

FY 2025-26 filings available

Novartis India Limited reported revenue of ₹376.96 Cr (down 3.4% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹377 Cr
-3.4% YoY
EBITDA
₹94.10 Cr
+2.9% YoY
Profit After Tax
₹93.20 Cr
-7.5% YoY
Net Worth
₹818 Cr
+4.2% YoY
Total Assets
₹835 Cr
+3.4% YoY
Total Debt
₹3.21 Cr
-36.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue377390367414487454533
Revenue growth-3.4%+6.3%-11.3%-15.0%+7.3%-14.8%-
EBITDA94.1091.4265.2665.08(22.53)26.7912.03
EBITDA margin+25.0%+23.4%+17.8%+15.7%-4.6%+5.9%+2.3%
Profit before tax130130123115(3.82)40.0428.64
Net profit93.2010183.2010340.9620.8710.09
Net profit margin+24.7%+25.8%+22.7%+25.0%+8.4%+4.6%+1.9%
EPS (₹)37.7640.8834.5241.88(1.51)8.474.08
Balance sheet
Total assets835808770828747856857
Net worth818785745776692711721
Total debt3.215.066.9721.5124.0162.4868.29
Cash & bank668648596556518499582
Net working capital625606544522498577592
Cash flow
Cash from operations46.7374.5711344.8038.67(69.21)(23.14)
Cash from investing17.63(3.31)33.13(153)87.0495.1655.91
Cash from financing(63.93)(64.15)(121)(30.48)(35.63)(36.80)(41.41)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue10490.5585.9090.3387.5583.8893.0087.10
Revenue growth (YoY)+18.6%+8.0%-7.6%+3.7%-5.1%---
Other income8.7410.018.759.4010.6110.6310.6010.32
Total expenses68.9069.9363.5466.4560.3159.9767.4269.14
EBITDA34.9120.6222.3623.8827.2423.9125.5817.96
EBITDA margin+33.6%+22.8%+26.0%+26.4%+31.1%+28.5%+27.5%+20.6%
Depreciation0.420.420.480.520.530.530.530.58
Interest0.060.070.980.110.100.120.360.14
Profit before tax43.1730.1429.6532.6537.2233.8935.2927.56
Tax10.964.8913.568.439.604.599.847.15

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 30 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue10490.5585.9090.3387.5583.8893.0087.10
Revenue growth (YoY)+18.6%+8.0%-7.6%+3.7%-5.1%---
Other income8.7410.018.759.4010.6110.6310.6010.32
Total expenses68.9069.9363.5466.4560.3159.9767.4269.14
EBITDA34.9120.6222.3623.8827.2423.9125.5817.96
EBITDA margin+33.6%+22.8%+26.0%+26.4%+31.1%+28.5%+27.5%+20.6%
Depreciation0.420.420.480.520.530.530.530.58
Interest0.060.070.980.110.100.120.360.14
Profit before tax43.1730.1429.6532.6537.2233.8935.2927.56
Tax10.964.8913.568.439.604.599.847.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue377390367414487454533
Revenue growth-3.4%+6.3%-11.3%-15.0%+7.3%-14.8%-
Other income38.7741.9661.6858.1133.1933.0936.14
Total expenses283299302348509427521
Employee cost21.0818.7222.9635.64102109114
EBITDA94.1091.4265.2665.08(22.53)26.7912.03
EBITDA margin+25.0%+23.4%+17.8%+15.7%-4.6%+5.9%+2.3%
Depreciation1.952.192.616.069.6512.1613.14
Interest1.260.771.491.754.837.686.39
Profit before tax130130123115(3.82)40.0428.64
Tax36.4829.5237.6512.02(0.10)19.1418.56
Net profit93.2010183.2010340.9620.8710.09
Net profit margin+24.7%+25.8%+22.7%+25.0%+8.4%+4.6%+1.9%
EPS (₹)37.7640.8834.5241.88(1.51)8.474.08
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital12.3412.3412.3412.3412.3412.3412.34
Reserves & surplus805773732763679699708
Shareholders' funds (net worth)818785745776692711721
Secured loans0.000.000.000.000.000.000.00
Unsecured loans3.215.066.9721.5124.0162.4868.29
Total debt3.215.066.9721.5124.0162.4868.29
Total liabilities835808770828747856857
Assets
Gross block9.379.0825.9731.1532.9474.8185.08
Net block2.884.546.9419.2523.6563.9176.28
Capital work in progress0.000.000.000.000.000.000.00
Investments0.000.000.000.000.000.000.00
Inventories53.3241.1144.8654.7257.0747.9558.68
Sundry debtors37.0540.1441.4736.1644.5638.7337.60
Cash & bank balances668648596556518499582
Loans & advances10.1816.5416.8530.5189.47138135
Total current assets768746699677709723813
Total current liabilities143140155155211146221
Net working capital625606544522498577592
Total assets835808770828747856857
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash52.0744.9619.4215868.2779.1287.76
Net cash from operating activities46.7374.5711344.8038.67(69.21)(23.14)
Net cash from investing activities17.63(3.31)33.13(153)87.0495.1655.91
Net cash from financing activities(63.93)(64.15)(121)(30.48)(35.63)(36.80)(41.41)
Net change in cash0.437.1125.54(139)90.08(10.85)(8.64)
Closing cash668648596556518499582
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-3.4%+6.3%-11.3%-15.0%+7.3%-14.8%-
EBITDA growth+2.9%+40.1%+0.3%+388.9%-184.1%+122.7%-
PBT growth-0.6%+6.2%+6.5%+9998.0%-+39.8%-66.6%
Net income growth-7.5%+21.1%-19.4%+151.9%+96.3%+106.8%-
Revenue CAGR (3Y)-3.0%-7.1%-6.8%-8.1%-0.3%-7.0%-6.7%
EBITDA CAGR (3Y)+13.1%-+34.6%+75.6%---21.7%
Profitability & leverage
Net income margin+24.7%+25.9%+23.2%+25.0%-0.8%+4.6%+1.9%
Return on capital employed+15.9%+16.6%+15.6%+14.9%+5.7%+5.6%+4.2%
Return on net worth+11.6%+13.2%+11.2%+14.1%+5.8%+2.9%+1.4%
Debt / equity0.010.010.020.030.060.090.05
Long-term debt / equity0.000.010.010.020.050.070.04
Interest cover1.370.862.382.97-15.0152.49-575.68
Efficiency & per share
Fixed asset turnover40.8622.2612.8412.909.035.689.77
Inventory turnover7.989.087.377.409.278.518.94
Debtors turnover9.779.569.4510.2511.6911.8912.81
EPS (₹)37.7640.8834.5241.88(1.51)8.474.08
Dividend per share (₹)25.0025.0025.0047.5010.0010.0010.00
Book value per share (₹)331.37318.06301.79314.29280.27288.16292.03

To see the full year-wise statements and ratios of Novartis India Limited, buy the company report.

Board of directors of Novartis India Limited

Novartis India has 6 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sanker Parameswaran
Also directs: Shri Balaji Valve Components Limited
Director22 Jun 20206 Years 4 MonthsCurrent
Shilpa Shashank JoshiWhole-Time Director22 Nov 20223 Years 11 MonthsCurrent
Christopher David SnookDirector01 Aug 200818 Years 2 MonthsCurrent
Falin Ishwarlal MajmudarWhole-Time Director28 Jun 20242 Years 4 MonthsCurrent
Gira Jagdeesh Sardesai
Also directs: Vinyl Chemicals (India) Limited, Ica Pidilite Private Limited
Director31 Mar 20242 Years 7 MonthsCurrent
Gowree Ashish Gokhale
Also directs: Spak Orgochem (India) Private Limited
Director01 Apr 20260 Years 6 MonthsCurrent
View all directors

Auditor

Novartis India Limited is audited by B S R & Co. LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
B S R & Co. LLPFY 2023101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 70.70%, foreign institutional investors hold 0.20%, domestic institutional investors hold 1.30% and retail and other public shareholders hold 27.80%.

Promoters: 70.70%DII (Domestic Institutional): 1.30%FII (Foreign Institutional): 0.20%Retail & Others: 27.80%
Sep 2026
QUARTER
70.70% Promoters
1.30% DII (Domestic Institutional)
0.20% FII (Foreign Institutional)
27.80% Retail & Others
Promoter holding - history
Now 70.70% · Sep 2026High 70.70% · Dec 2025Low 70.70% · Dec 2025
69%69.8%70.5%71.3%72%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 70.70%Mar 2026: 70.70%Jun 2026: 70.70%Sep 2026: 70.70%70.70%70.70%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters70.70%70.70%70.70%70.70%
Public29.30%29.30%29.30%29.30%

Charges & borrowings

Open charges
None
Satisfied charges
₹257.48 Cr
Breakdown by lending institutions
Grindlays Bank₹111.60 Cr
Allahabad Bank₹45.00 Cr
Bnp Paribas₹33.00 Cr
Nationale De Paris French Bank Building₹32.50 Cr
The Industrial Credit and Investment Corpn. of India Ltd.₹20.00 Cr
Others₹15.38 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
12 Apr 199990232124Bnp Paribas₹33 CrSatisfied
02 May 199890229347The Hongkong and Shanghai Banking Corporation Ltd.₹5 CrSatisfied
21 Jul 199390228667Grindlays Bank₹45 CrSatisfied
21 Jul 199390230751Allahabad Bank₹45 CrSatisfied
28 May 199290228548Grindlays Bank₹38 CrSatisfied

To see the full charge records of Novartis India Limited, buy the company report.

Total charge records: 21 View all charges

Deals & funding

Novartis India Limited has 12 deals on record (8 market trades, 4 secondary share transfers); the latest was in September 2026.

Total deals
12
Market trades
8
Secondary share transfers
4

Deals on record (5 of 12)

WhenDealAmountParties
Sep 2026Market trade₹21.72 CrBuyer: an individual
Seller: Kyrush Investments
Aug 2019Secondary share transferUndisclosedBuyer: Atul Limited , Others - Novartis India Limited, Safina Towers Private Limited , an individual
Seller: The Oriental Insurance Company Limited , 3 individuals
Jul 2018Secondary share transferUndisclosedBuyer: 4 individuals
Seller: Others - Novartis India Limited, an individual
Jan 2018Secondary share transferUndisclosedSeller: Others - Novartis India Limited
Aug 2007Market trade₹49.43 CrBuyer: Nippon Life India Trustee Limited
Seller: Icici Prudential Asset Management Co.Ltd.

To see the full deal history of Novartis India Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Novartis India Limited has 15 MSME Form 1 returns on record between 2019 and 2024, listing 1,341 overdue payments to 43 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 43)

SupplierAmount dueDue sinceReported on
S.B. Warehousing & Logistics Private Limited
an individual supplier
an individual supplier
C-Quel Management Services Private Limited
Medulla Communications Private Limited

To see the full MSME payment records of Novartis India Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Novartis India Limited has a workforce of 59 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.

Employee count
59
Active EPFO establishments
1
Employee growth
-16.9%

GST

Novartis India has 24 GST registrations: 23 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
24
Active
23
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AAACH2914F1ZYMaharashtraActive01 Jul 2017
27AAACH2914F2ZXMaharashtraActive26 Feb 2019
03AAACH2914F1Z8PunjabActive01 Jul 2017
04AAACH2914F1Z6ChandigarhActive01 Jul 2017

To see the full GST registrations and return filing status of Novartis India Limited, buy the company report.

Recent activity

Novartis India Limited has 43 board changes on record since 1998: 25 appointments and 18 cessations. The latest: Gowree Ashish Gokhale was appointed as Director on 01 Apr 2026.

Appointed
Gowree Ashish Gokhale was appointed as Director.
Filing
Novartis India Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Novartis India Limited last Annual general meeting of members was held on 31 Jul 2025 as per latest MCA records.
Charges
A charge registered on 06 Aug 1940 via Charge ID 90230132 with The National Bank Of India Ltd. was fully satisfied on 20 Aug 2024.
Charges
A charge registered on 21 Jul 1993 via Charge ID 90228667 with Grindlays Bank was fully satisfied on 01 Jul 2024.
Charges
A charge registered on 17 Aug 1982 via Charge ID 90227632 with Grindlays Bank was fully satisfied on 01 Jul 2024.
Appointed
Falin Ishwarlal Majmudar was appointed as Whole-Time Director.
Charges
A charge registered on 13 Feb 1992 via Charge ID 90228501 with The Industrial Credit And Investment Corpn. Of India Ltd. was fully satisfied on 30 Apr 2024.
Charges
A charge registered on 13 Feb 1992 via Charge ID 90230694 with The Industrial Credit And Investment Corpn. Of India Ltd. was fully satisfied on 30 Apr 2024.
Ceased
Nikhil Malpani ceased to be Company Secretary.
Charges
A charge registered on 25 Jun 1980 via Charge ID 90227549 with Citi Bank N. A. was fully satisfied on 10 Apr 2024.
Ceased
Sanjay Prabhakar Murdeshwar ceased to be Managing Director.

83 earlier events are in the company report.

News

Frequently asked questions

Novartis India is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 13 December 1947 (79+ years old) and is registered under CIN L24200MH1947PLC006104. Listed on BSE: 500672 and NSE: NOVARTIND.

Novartis India reported revenue of ₹376.96 Cr for FY 2025-26 (down 3.4% YoY) based on standalone financials.

Novartis India has 6 current directors:

The latest financial statements of Novartis India on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 31 July 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Novartis India is 27AAACH2914F1ZY, registered in Maharashtra. The company has 24 GST registrations in all, of which 23 are active and 1 is cancelled or inactive. Other active GSTINs include 27AAACH2914F2ZX (Maharashtra), 03AAACH2914F1Z8 (Punjab), 04AAACH2914F1Z6 (Chandigarh).

The CIN (Corporate Identification Number) of Novartis India is L24200MH1947PLC006104. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Novartis India is a listed company as per MCA records. Its shares are listed on both BSE (code: 500672) and NSE (symbol: NOVARTIND).

Novartis India has 344 court cases on record: 173 filed by the company and 175 filed against it. 57 are pending. Most are in the high courts.

Novartis India was incorporated on 13 December 1947, making it 79+ years old. It is registered with the Registrar of Companies, Mumbai.

Novartis India has 12 deals on record (8 market trades, 4 secondary share transfers); the latest was in September 2026.

Gowree Ashish Gokhale was appointed as Director on 01 Apr 2026. Falin Ishwarlal Majmudar was appointed as Whole-Time Director on 28 Jun 2024. Nikhil Malpani ceased to be Company Secretary on 30 Apr 2024. Novartis India has 43 board changes on record in total.